Synthesis of GnRH and somatostatin cytotoxic drug conjugates by Schuster, Sabine
Synthesis of GnRH and Somatostatin  
Cytotoxic Drug Conjugates 
 
Sabine Schuster 
Booklet of the PhD thesis 
Supervisor 
Prof. Dr. Gábor Mező 
Head of the Research Group of Peptide Chemistry 
Doctoral School of Chemistry 
Head of Doctoral School: Dr. Attila Császár 
Doctoral Program:  
Synthetic Chemistry, Materials Science and Biomolecular Chemistry 
Director of the Program: Prof. Dr. András Perczel 
 
Department of Organic Chemistry 
MTA-ELTE Research Group of Peptide Chemistry  
Eötvös Loránd University, Faculty of Science 




Cancer is the second leading cause of death worldwide and was responsible for more than 9 
million deaths in 2018 [1]. Targeted tumor therapy is a promising tool to overcome the 
drawbacks of traditional chemotherapy, like the lack of selectivity and harmful side effects to 
healthy tissue. The basis of this approach is the overexpression of tumor specific cell surface 
proteins, like peptide hormone receptors. Natural ligands or related high affinity binders of 
these receptors are promising targeting moieties for the selective delivery of cytotoxic agents 
to tumor cells. Prominent examples are the two peptide hormones, gonadotropin-releasing 
hormone (GnRH) and somatostatin (SST). Both hormones are of high clinical relevance and 
their synthetic analogs are used as therapeutics for the treatment of hormone related cancer [2]. 
Considering that GnRH and SST analogs exert not only an indirect antitumor activity by 
inducing hormonal dysfunctions, but also elicit a direct antiproliferating activity by binding to 
their highly expressed receptors on tumor cells, both peptide hormones are valuable candidates 
for the development of drug delivery systems (DDS). The first cytotoxic GnRH and SST 
derivatives have been developed in the 1980s, whereby intensive preclinical studies illustrate 
the high value of doxorubicin (Dox) and 2-pyrrolino-Dox (pyDox)-linked GnRH and SST 
derivatives [3–5]. 
Next to human GnRH (GnRH-I), the natural sea lamprey isoform GnRH-III (Glp-His-Trp-Ser-
His-Asp-Trp-Lys-Pro-Gly-NH2, Glp is pyroglutamic acid) represents a promising homing 
device for GnRH-based drug delivery systems (DDS). This weak GnRH agonist binds to 
GnRH-receptors (GnRH-R) on cancer cells and induces a direct antitumor activity, while its 
endocrine effect is strongly reduced compared to GnRH-I [6]. Based on these findings, a huge 
variety of GnRH-III-based DDS have been developed in our laboratories where daunorubicin 
(Dau) was linked to the lysine side chain of GnRH-III via oxime bond formation to an inserted 
aminooxyacetyl (Aoa) moiety [7–10]. It could be shown that these conjugates are highly stable in 
circulation and exert a substantial growth inhibitory effect on cancer cells. Although this linker 
system prevents the intracellular release of the free drug, it was demonstrated that lysosomal 
enzymes ensure the formation of active drug-containing metabolites which are able to 
intercalate into DNA strands and thus, inhibit macromolecule biosynthesis which is 
accompanied with reduced cell proliferation [8]. Moreover, the results pointed out that the DNA 
binding affinity is slightly diminished in comparison to the free Dau. In the recent years, 
different systematical refinement studies have been performed to improve the antitumor activity 
of the oxime bond-linked GnRH-III-Dau conjugates, resulting in our lead compound GnRH-
III-[4Lys(Bu),8Lys(Dau=Aoa)] (K2) (where Lys(Bu) is butyrylated lysine) which induces a 
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strong in vitro and in vivo antitumor activity on GnRH-R expressing cells [10,11]. 
Apart from that, synthetic derivatives of SST, a cyclic neuroendocrine peptide, have been used 
as carriers to deliver cytotoxic drugs to SST receptor expressing cancer cells. Next to the market 
approved SST analogs octreotide and lanreotide, two other SST compounds, namely RC-121 
(D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2) and TT-232 (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-
Thr-NH2) (cyclized by disulfide bond), provide valuable benefits for targeted tumor therapy 
[12,13]. RC-121 possesses a highly enhanced potency and longer duration of action for inhibition 
of growth hormone release than native SST [12]. Moreover, it exhibits a significant in vitro and 
in vivo inhibitory effect on different cancer cells and has been successfully used as peptide 
carrier for drug delivery [4,5]. Considering that all 5 naturally occurring SST receptors (SSTR1-
5) are also present with varying incidence on tumor cells, a selective targeting of one or two 
SSTRs would be favorable. It could be shown that RC-121 binds with high affinity to SSTR2 
and with moderate affinity to SSTR5, while TT-232 displayed the highest affinity for SSTR4, 
followed by moderate affinity to SSTR1 and SSTR5 [5,13]. In comparison to RC-121, TT-232 
has no growth hormone release inhibitory activity, but exerts a strong in vitro and in vivo 
antineoplastic activity on a wide range of malignant tumors, including breast, prostate and colon 
cancer [13]. Therefore, TT-232 represents a valuable candidate for targeted tumor therapy 
without causing undesirable endocrine effects. 
2. Aims and objectives 
Based on these research findings, the central goal of my thesis was the development and 
evaluation of GnRH- and somatostatin-based drug delivery systems for targeted tumor therapy. 
Moreover, certain main objectives have been defined: 
1. Improvement of the antitumor activity of oxime bond-linked GnRH-III-Dau conjugates: 
 synthesis of oxime bond-linked GnRH-III-Dau conjugates, using solid phase peptide 
synthesis (SPPS) and ligation of Dau in solution and evaluation of the cytostatic effect of 
the compounds in comparison to K2 by cell viability assays 
 additional analyses of (best) candidates to analyze the cellular uptake (flow cytometry) 
and localization (confocal laser scanning microscopy (CLSM)), stability in plasma and in 
presence of lysosomal enzymes (LC-MS assay) and GnRH receptor affinity by radio 
ligand binding studies in order to validate the results of the cell viability assays and to 
prove the mechanism of action of the conjugates 
2. Development of cleavable linker containing GnRH-drug conjugates:  
 synthesis of targeting moieties by SPPS (best carriers from the 1. objective) and synthesis 
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of paclitaxel (PTX) and Dau-containing linker systems in solution consisting of Val-Ala 
or Val-Cit cathepsin B cleavage site and a para-aminobenzyloxycarbonyl (PABC) self-
immolative spacer, followed by attachment to carrier 
 synthesis of non-cleavable counterparts as controls 
 evaluation and comparison of cytostatic effect of the conjugates to gain information about 
the impact of the linker system 
 proof of linker concept by lysosomal degradation studies and receptor binding studies 
3. Comparison of different SST carriers and linker systems to establish a new SST lead 
compound:  
 synthesis of 5(6)-carboxyfluorescein (FAM) labeled SST-compounds by SPPS and 
cellular uptake studies of the FAM compounds by CLSM and flow cytometry  
 synthesis of equivalent oxime bond-linked SST-Dau conjugates and analysis of the 
cytostatic effect to select the best targeting moiety  
 synthesis of additional SST-conjugates with different linker systems and evaluation of 
their cytostatic effect to choose the most promising one 
 synthesis of 2-pyrrolino-Dau (pyDau) SST conjugate using the best carrier-linker 
combination and evaluation of the antitumor activity  
3. Methods 
The GnRH-III and SST peptide moieties were synthesized by solid phase peptide synthesis 
(SPPS) according to Fmoc/tBu chemistry on Rink-Amide MBHA or Fmoc-Ethyl-Indole AM 
resin and the oxime bond ligation was carried out in 0.2 M NH4OAc buffer and stirred 
overnight, whereby the carbonyl group of Dau was used for conjugation via oxime bond 
formation [10]. The SST-derivatives were cyclized either by disulfide bond formation (air 
oxidation) or thioether bond formation in aqueous, alkaline buffer. 
For the synthesize of cleavable GnRH-drug conjugates, dipeptidyl-PABC-drug linkers were 
prepared in solution as recently reported [14,15]. Dau and PTX were used as payloads. The amino 
group of the Dau sugar was used as ligation site to connect the PABC moiety by carbamate 
group formation. PTX was linked to its C2’-OH group by carbamate group formation to an 
N,N’-dimethylethylenediamine (here further named as diamine) spacer. This spacer was 
attached to the PABC moiety. A glutaryl spacer was added to the N-terminus to facilitate the 
conjugation of the linker to 8Lys of the GnRH-III carriers by amide bond formation, affording 
glutaryl-Val-Aaa-PABC-Dau and glutaryl-Val-Aaa-PABC-diamine-PTX linkers. Besides, 
5 
 
non-cleavable linkers have been also synthesized, namely glutaryl-Dau and glutaryl-diamine-
PTX. Each linker was coupled to both peptide carriers affording 12 novel GnRH-III conjugates. 
All conjugates were purified by preparative RP-HPLC and characterized by analytical HPLC 
and ESI-MS. 
The cytostatic effect of the conjugates was determined by resazurin- or MTT-based cell 
viability assay. Therefore, cells were treated for 24 hours (Dau-conjugates) or 6 hours (PTX-
conjugates) one day after seeding, followed by wash out of the compounds. The cell viability 
was determined 72 hours after treatment initiation. 
The cellular uptake of the compounds was investigated by flow cytometry or CLSM. For both 
experiments, the cells were treated for 6 hours. Flow cytometry studies were performed on a 
BD LSR III flow cytometer. For the CLSM studies, cells were seeded on cover glasses. After 
treatment period, the cover glasses were mounted to microscopy slides. The images were 
recorded on a Zeiss LSM 710 system 
The stability in human plasma and the lysosomal degradation studies in presence of rat liver 
lysosomal homogenate were performed as recently described [8]. The sample analysis was 
performed by LC-MS. 
The radioligand binding studies with radiolabeled triptorelin (GnRH-I-[6D-Trp]) were 
measured in the same manner as recently reported [10]. 
4. New results 
4.1. GnRH-drug conjugates 
Improvement of the antitumor activity of oxime bond-linked GnRH-III-Dau conjugates  
1. We synthesized and analyzed novel GnRH-III derivatives with unnatural amino acids (Aaa) 
within the peptide sequence. Two different strategies have been followed yielding two different 
sets of GnRH-III-Dau conjugates: 
 1st set of GnRH-III-Dau conjugates: 6Asp was substituted by D-Asp, D-Glu and D-Trp. 
 2nd set of GnRH-III-Dau conjugates: this set comprises different changes, including 
modification of the C-terminus from -Pro-Gly-NH2 to -Pro-ethylamide (EA), methylation 
of 6Asp to 6Asp(OMe), 3Trp exchanged by 3D-Trp or 3D-Tic (1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid), as well as the combination of 3D-Tic with 7D-
Trp and all 3D-Tic-conjugates in combination with 2His deletion. 
2. All GnRH-III-Dau-conjugates of the 1st set revealed a substantial growth inhibitory effect on 
estrogen-dependent breast and reproductive system unrelated colon cancer cells, but none of 
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the novel 6D-Aaa GnRH-III conjugates revealed a higher biological activity than our lead 
compound K2. 
3. Based on further experiments, we could demonstrate that the anticancer activity of the 
conjugates strongly depends on the cellular uptake and the efficient release of the small drug 
metabolites by lysosomal enzymes. 
4. CLSM studies were used to verify the endocytic uptake of our lead compound K2. Time-
dependent uptake studies pointed out that Dau reached its site of action already within 10 
minutes treatment period which was validated by co-staining of the nuclei. At lower time points, 
the Dau-signal was predominantly detected in small cytosolic vesicles which were proposed to 
be lysosomes or endosomes. This assumption could be confirmed by co-staining of the 
lysosomes. 
5. The GnRH-R mediated uptake could be further verified by performing a receptor competition 
assay with GnRH-I superagonist triptorelin. We could also show that the use of increasing 
triptorelin concentrations and constant concentration of K2 reduce the cellular uptake rate of 
K2 substantially.  
6. Considering that the first modifications did not result in the desired improvement of the 
antitumor activity, further modifications have been applied and the growth inhibitory effect of 
the compounds was studied initially on human estrogen dependent MCF-7 breast and hormone 
independent HT-29 colon cancer cells. The results revealed a clearly improved anticancer 
activity of compound GnRH-III-[2ΔHis,3D-Tic, 4Lys(Bu), 8Lys(Dau=Aoa)] (16) on both cell 
lines, whereby this effect was higher on breast cancer cells. Furthermore, the activity of K2 and 
16 was investigated on estrogen independent MDA-MB-231 breast cancer cells. We obtained 
an improved anticancer activity of 16 over K2 also on this cell line, indicating that the activity 
was not exclusively increased on estrogen dependent breast cancer cells. 
7. In order to better interpret these results, a variety of comparable studies between K2 and 16 
have been performed. Hence, the degradation of K2 and 16 by lysosomal enzymes was 
analyzed, demonstrating that the N-terminal region of 16 shows a higher durability towards 
lysosomal proteases. However, the release of the smallest active metabolite (H-Lys(Dau=Aoa)-
OH) could be obtained for both conjugates within the first hour, since the degradation of the C-
terminus was not affected which might be of high relevance for the biological activity of the 
oxime bond linked GnRH-III-Dau conjugates.  
8. Cellular uptake studies on MCF-7 breast and HT-29 colon cancer cells by flow cytometry 
pointed out that compound 16 was taken up more efficiently than K2. This effect could be 
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particularly demonstrated in case of smaller concentrations of the conjugates. Moreover, the 
uptake rates were higher on estrogen dependent breast cancer cells than on colon cancer cells, 
being in line with the results of the cytostatic effect analysis. Moreover, we demonstrated that 
the receptor binding affinity of 16 is slightly better than that of K2. According to these results, 
it can be assumed that the improved anticancer activity is related to an enhanced cellular uptake 
of 16. 
9. The time-dependent cellular uptake of compound 16 was studied by CLSM. We could detect 
the Dau-signal already after 5 minutes of treatment period in nuclei which was faster than the 
delivery of Dau to its site of action by K2 (see above), revealed in comparable studies. Taking 
this into account, it can be proposed that the improved cellular uptake of 16 is accompanied 
with an accelerated delivery of the drug. 
10. The stability of both compounds was measured in presence of human and mouse blood 
plasma, whereby no degradation could be obtained within 24 hours incubation at 37 °C. This is 
of great importance for the stability of the compounds in circulation and the selective delivery 
of the compounds to cancerous, GnRH-R expressing cells. Moreover, the high durability in 
mouse plasma provides a good basis for upcoming in vivo studies on tumor bearing mice. 
Development of cleavable linker containing GnRH-drug conjugates 
1. We established the synthesis route of cleavable self-immolative linker-containing GnRH-
Dau and -PTX conjugates and related non-cleavable compounds. Based on the results of K2 
and 16, the corresponding peptide carriers were used as targeting moiety. To ensure the release 
of the free drug, self-immolative PABC linker systems with cathepsin B cleavable sites (Val-
Ala or Val-Cit) were used to link the drugs.  
2. We determined the growth inhibitory effect of the conjugates on human A2780 ovarian 
cancer cells which highly express GnRH-Rs, and Panc-1 pancreatic cancer cells, revealing a 
lower level of GnRH-R expression. All cleavable linker containing conjugates displayed an 
effective cell growth inhibition on ovarian cancer cells, while the activity of the non-cleavable 
linker derivatives was strongly reduced, indicating the high value of the self-immolative linker 
systems. Moreover, we could show that the antitumor activity on pancreatic cells was reduced 
by approximately one order of magnitude, compared to the results obtained on ovarian cancer 
cells which seems to be caused by the selectivity of the compounds towards GnRH-R 
expressing cells. Furthermore, we could demonstrate that the Dau-compounds with the new 
targeting sequence revealed higher activities than the compounds with the K2-derived peptide 
carrier which further underlines the valuable character of the novel GnRH-targeting moiety. In 
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contrast, we detected comparable cell growth inhibitory effects for the cleavable PTX-
conjugates. The direct comparison of the oxime bond-linked Dau-compounds K2 and 16 
showed that both compounds have a slightly improved anticancer activity on GnRH-R 
expressing ovarian cancer cells than the self-immolative counterparts. 
3. We could validate the releasing concept of the self-immolative linkers by lysosomal 
degradation of distinct Dau and PTX conjugates. Thus, we demonstrated that Dau was 
efficiently released from both linker systems within the first hour, whereby the release was 
slightly faster for the Val-Cit-linker. In comparison, the liberation of Dau could not be detected 
for the non-cleavable linkers. These results clearly prove the releasing concept of the Dau-
conjugates indicating that the slightly reduced activity is not related to an insufficient Dau 
release. In case of the PTX conjugates, we could detect the release of the diamine-PTX fragment 
for both cleavable linker systems already after 5 minutes of incubation, but the release of the 
free drug was not observed within 24 hours of incubation which might explain the similar 
antitumor activities of the compound. In case of the non-cleavable PTX conjugate, the release 
of the diamine-PTX was not detected. 
4. The GnRH-receptor binding affinities of the cleavable GnRH-III Dau derivative with the best 
anticancer activity and its PTX equivalent have been determined, revealing that the affinity of 
the cleavable Dau-derivative was reduced by a factor of 7 compared to compound 16, while the 
affinity of the PTX-compound was 4-times reduced. This leads to the assumption that the 
decreased receptor binding affinity has a larger influence on the biological activity than the 
reduced DNA binding properties of the smallest Dau-containing metabolite of the oxime bond 
Dau conjugates. 
4.2. Somatostatin conjugates 
Comparison of different SST carriers and linker systems to establish a new SST lead compound 
FAM-labeled somatostatin conjugates 
1. To compare the two SST targeting moieties RC-121 and TT-232 with a novel targeting 
moiety which possesses the same ring size as RC-121, but is cyclized by a thioether bond, we 
synthesized fluorescently labeled compounds. 
2. Flow cytometry studies showed that the RC-121 targeting moiety was taken up most 
efficiently on breast, as well as colon cancer cells, followed by the TT-232 derivative and then 
the thioether compound. Moreover, we could show that the incorporation of a hydrophilic linker 
has a positive impact on the uptake rate of the compounds.  
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3. The images of the CLSM studies on breast cancer cells displayed strong fluorescent signals 
in the cytosol for the linker containing compounds, while in case of the conjugates without 
linker, cytosolic vesicles have been predominantly detected. According to these results, we can 
conclude that the LRRY-spacer did not only enhance the cellular uptake, but also ensured the 
release of FAM-containing fragments, whereas the N-terminal D-Phe of the compounds without 
linker prevents this release. 
Somatostatin-drug conjugates 
1. We developed comparable oxime bond-linked Dau=Aoa-LRRY-derivatives and determined 
their cytostatic effect on human colon cancer and estrogen dependent breast cancer cells. These 
studies pointed out that the RC-121-Dau compound was the most efficient on both cell lines. 
On the contrary, the TT-232-Dau conjugate revealed a low cytostatic activity on colon cancer 
cells, while its activity was clearly improved on breast cancer cells. The thioether bond 
containing Dau-conjugate revealed comparable activities on both cell lines, thereby it was more 
effective on colon cancer cells and less active on breast cancer cells than the TT-232-Dau 
conjugate. Due to these results, we assume that breast cancer cells express a higher amount of 
SSTR4 than colon cancer cells, while SSTR2 expression seems to be similar on both cell lines.  
2. We established the synthesis of two new RC-121-Dau conjugates with different linker 
systems, one linker system was Dau=Aoa-LRRYC-NH2 which was attached by thioether bond 
formation to an N-terminally inserted chloroacetyl moiety of RC-121 and the other was 
glutaryl-Val-Ala-PABC-Dau which revealed the best activity in the GnRH study. This linker 
was directly coupled to the N-terminal D-Phe of RC-121 by amide bond formation. 
3. In direct comparison on human breast and colon cancer cells, the initial oxime bond-linked 
Dau=Aoa-LRRY-RC-121 compound was again evaluated as the conjugate with the highest 
anticancer activity, directly followed by the self-immolative linker containing compound. The 
thioether linker derivative showed a lower growth inhibitory effect than the other two 
compounds and a slightly better effect than the novel thioether cyclized derivative of the initial 
study.  
4. These results prompted us to ligate the highly potent Dau derivative pyDau to the Aoa-
LRRY-RC-121 peptide by oxime bond formation. The resulting compound displayed a 20-35-
times improved growth inhibitory effect on breast and colon cancer cells. This strong anticancer 




Since many cancer cells overexpress receptors for the peptide hormones GnRH and 
somatostatin, their ligands can be used as homing devices to deliver cytotoxic cargos selectively 
to cancer cells. Hence, the present thesis deals with the synthesis and biochemical 
characterization of novel GnRH-III and SST-drug conjugates. 
A variety of GnRH-III-Dau conjugates have been established and systematically refined in our 
research group. To achieve an improved antitumor activity of oxime bond-linked GnRH-III-
Dau compounds, 20 novel conjugates with modified peptide sequence have been prepared. The 
in vitro cytostatic effect of these derivatives was studied on GnRH-R expressing cancer cells 
and compared to our lead compound K2. The conjugate GnRH-III-[2ΔHis-3D-Tic-4Lys(Bu), 
8Lys(Dau=Aoa)] (16) displayed a significantly improved antitumor activity. Besides, cellular 
uptake and localization studies, stability analysis in plasma and degradation by lysosomal 
enzymes, as well as receptor binding studies have been performed. We could show that the 
increased biological activity is mainly related to the improved cellular uptake of 16. Moreover, 
the results of the studies underline the high potential of 16 for targeted tumor therapy. 
Further GnRH-III-drug conjugates were established using the best targeting moieties. The anti-
cancer drugs PTX and Dau were linked to the peptides using cathepsin B labile, self-immolative 
linkers. Cell viability studies on human cancer cells verified the cytostatic effect of the cleavable 
GnRH-III derivatives. Moreover, the drug releasing concept was validated by lysosomal 
degradation studies. In summary, we could show that next to the release of the free drug, the receptor 
binding affinity and the cellular uptake are very important factors for the anticancer activity. 
In addition, SST-drug conjugates were prepared and evaluated. Initially, the potential of 
different targeting moieties was analyzed. Thus, FAM-labeled derivatives were developed to 
determine the cellular uptake of the compounds. Due to these results, related oxime bond-linked 
Dau-conjugates were synthesized, and the cytostatic effect was studied on SSTR expressing 
cancer cells. The best targeting moiety was selected and used to study the influence of distinct 
linker systems on the anticancer activity. The best candidate consists of the RC-121 carrier and 
the drug linker Dau=Aoa-LRRY. To further enhance the antitumor activity, the highly potent 
anticancer drug 2-pyrrolino-daunorubicin was used instead of Dau affording conjugate 
pyDau=Aoa-LRRY-RC-121 (71) which revealed a strongly increased in vitro anticancer 
activity. Thus, this SST conjugate is a highly promising candidate for targeted cancer therapy. 
Our results confirm the high potential of compound 16 and 71 for selective cancer therapy which 
underlines the great value of GnRH-III and SST-drug conjugates for targeted tumor therapy. 
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